{
    "clinical_study": {
        "@rank": "20123", 
        "arm_group": {
            "arm_group_label": "SyB L-0501", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate safety and efficacy of SyB L-0501 after 2-day\n      intravenous infusion at a dose of 100 mg/m2/day to patients with chronic lymphocytic\n      leukemia."
        }, 
        "brief_title": "Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients meeting all of the following criteria are to be included in the study:\n\n          1. Patients aged between 20 and 80 years (at the time of registration)\n\n          2. Patients who have provided written consent in person for participation in this study\n\n          3. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0\n             to 2\n\n          4. Patients who are expected to survive for at least 3 months\n\n          5. Patients who are naive to or not suitable for fludarabine therapy\n\n          6. Patients who are documented with chronic lymphocytic leukemia on the basis of IWCLL\n             guideline:\n\n               -  The presence of \u2265 5000/mm3 monoclonal mature B-lymphocytes in the peripheral\n                  blood\n\n               -  \u2264 55 % atypical lymphocytes, prolymphocyte-like cells, and lymphoblasts with\n                  prominent nucleoli\n\n               -  For monoclonal mature B-lymphocytes, at least one of the B-cell specific\n                  differentiation antigens (Cluster of differentiation (CD) 19, CD 20, and CD 23)\n                  and CD 5 is positive by flow cytometry\n\n          7. Patients in Stage C or stage B with active disease based on Binet staging system (at\n             the time of registration)\n\n               -  Decision to start treatment should be made upon IWCLL guideline criteria.\n\n               -  Active disease is defined to meet at least one of the following criteria.\n\n                    1. Progression and/or worsening of anemia and/or thrombocytopenia caused by\n                       decreased bone marrow function.\n\n                    2. Massive (6 cm below the left costal margin) or progressive or symptomatic\n                       splenomegaly\n\n                    3. Massive nodes (\u226510 cm in longest diameter) or progressive or symptomatic\n                       lymphadenopathy\n\n                    4. Progressive lymphocytosis with an increase of > 50% over a 2-month period,\n                       or lymphocyte doubling time of less than 6 months\n\n                    5. Autoimmune anemia and/or thrombocytopenia poorly responsive to\n                       corticosteroids or other standard therapy\n\n                    6. B symptoms Weight loss > 10% within the previous 6 months Fevers of greater\n                       than 38.0\u00b0 C for 2 or more weeks without other evidence of infection Night\n                       sweats\n\n          8. Patients with 2 or less regimens of previous chemotherapy including antibody therapy.\n             Corticosteroid monotherapy is not counted.\n\n          9. Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung,\n             liver, and kidney functions)\n\n               -  Neutrophil count: \u2265 1,000 /mm3\n\n               -  Aspartate aminotransferase(AST) Glutamic oxaloacetic transaminase(GOT): \u2264 3.0\n                  times the upper limit of normal range at each site\n\n               -  Alanine aminotransferase (ALT) Glutamic pyruvic transaminase(GPT): \u2264 3.0 times\n                  the upper limit of normal range  at each site\n\n               -  Total bilirubin: \u2264 1.5 times the upper limit of normal range  at each site\n\n               -  Serum creatinine: \u2264 1.5 times the upper limit of normal range  at each site\n\n               -  Partial pressure of O2 (PaO2): \u2265 65 mmHg\n\n               -  No abnormalities which require treatment are detected on ECG\n\n               -  Left ventricular ejection fraction (LVEF) (echocardiography): \u2265 55%\n\n        Exclusion Criteria:\n\n        Patients who fall under any one of the following criteria are to be excluded\n\n          1. Patients who have been without treatment for less than 4 weeks after prior treatment.\n             For patients treated with antibody therapy or underwent hematopoietic stem cell\n             transplantation, for 3 months after prior treatment\n\n          2. Patients who enrolled other clinical studies within 4 weeks before registration for\n             this study\n\n          3. Patients who received allogeneic stem cell transplantation in the past\n\n          4. Patients with defective p53 (17p-) confirmed by chromosome analysis (Fluorescence in\n             situ hybridization (Fish) method)\n\n          5. Patients who are clinically diagnosed with Richter's syndrome\n\n          6. Patients with infiltration to the central nervous system (CNS) or patients with\n             clinical symptoms of suspected infiltration to the CNS\n\n          7. Patients with multiple primary cancers or patients with a history of other malignant\n             tumors within past 5 years, except for basal cell or squamous cell skin cancer, or\n             carcinoma in situ of the cervix or gastrointestinal tract\n\n          8. Patients with serious bleeding tendencies (e.g., disseminated intravascular\n             coagulation (DIC))\n\n          9. Patients with, or confirmed in the past to have had, interstitial lung disease or\n             pulmonary fibrosis\n\n         10. Patients with, or confirmed in the past to have had, autoimmune hemolytic anemia\n             responds to corticosteroid therapy\n\n         11. Patients with any of the following complications\n\n               -  serious cardiac disease (e.g., myocardial infarction, ischemic heart disease, or\n                  arrhythmia requiring treatment)\n\n               -  serious, active infections (requiring intravenous administration of antibiotics,\n                  antifungal drugs, or antiviral drugs)\n\n               -  hepatic or renal dysfunction\n\n               -  accumulation of pleural effusion, pericardial effusion, or peritoneal effusion\n\n               -  uncontrollable serious gastrointestinal disease, endocrine disorder, or mental\n                  illness\n\n         12. Patients who received SyB L-0501 in the past\n\n         13. Patients with allergies to mannitol\n\n         14. Patients who need cytokine preparations such as erythropoietin or granulocyte colony\n             stimulating factor (G-CSF) or blood transfusions at registration for this study\n\n         15. Patients positive for HIV antibody or Hepatitis C virus (HCV) antibody\n\n         16. Patients positive for Hepatitis B surface (HBs) antigen. Patients with negative\n             results will also be checked for Hepatitis B core (HBc) antibody and HBs antibody. If\n             either of the test results is positive, measure Hepatitis B virus (HBV)-DNA and\n             exclude the patients with results above sensitivity\n\n         17. Patients with clinical symptom of cytomegalovirus (CMV) infection, except\n             asymptomatic patients with CMV positive\n\n         18. Patients who are pregnant, who may possibly be pregnant, or lactating\n\n         19. Patients who do not agree to practice contraception. Male: During investigational\n             product administration and until 6 months after final administration Female: During\n             investigational product administration and until 4 months after final administration\n\n         20. Patients with drug addiction, narcotics addiction, and/or alcohol dependency\n\n         21. Patients otherwise judged by the investigator or sub-investigator to be unsuitable\n             for inclusion in this study"
            }, 
            "gender": "Both", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042911", 
            "org_study_id": "2012003"
        }, 
        "intervention": {
            "arm_group_label": "SyB L-0501", 
            "description": "SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued  from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.", 
            "intervention_name": "SyB L-0501", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan", 
                        "state": "Aichi"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuyama", 
                        "country": "Japan", 
                        "state": "Hiroshima"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izumo", 
                        "country": "Japan", 
                        "state": "Shimane"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma", 
        "overall_contact": {
            "email": "skinoshita.0709@symbiopharma.com", 
            "last_name": "Seiji Kinoshita", 
            "phone": "+81-3-5472-1127"
        }, 
        "overall_official": {
            "affiliation": "SymBio Pharmaceuticals", 
            "last_name": "Toshihiko Nagase", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The criteria for CR, CRi, nPR and PR based on IWCLL guideline are shown below. For the criteria for nPR and PR, please refer to the description of NCI-WG response rate (CR+nPR+PR).\nCR: Assessment should be made at least 8 weeks after completion of administration.\nAbsence of significant lymphadenopathy (lymph nodes greater than 1.5 cm in diameter)\nNo hepatomegaly or splenomegaly\nAbsence of B symptoms\nMeet the following laboratory test values;\nlymphocyte count in peripheral blood: \uff1c4.0\u00d710^9/L\nneutrophil count: \uff1e1.5\u00d710^9/L\nplatelet count: 100\u00d710^9/L\nhemoglobin: 11.0 g/dL without transfusions\nless than 30% of nucleated cells are lymphocytes (confirmed by bone marrow aspiration and no lymphoid nodules).\nNo new lesion emergence\nCRi: Fulfills all of the following criteria\nDelayed anemia, thrombocytopenia, or neutropenia is observed.\nFulfills all CR criteria other than 4).\nDelayed symptoms are all judged to be caused by drug.", 
            "measure": "Response rate [complete remission (CR) +complete remission / incomplete (CRi) + nodular partial remission (nPR) + partial remission (PR)] based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guideline", 
            "safety_issue": "No", 
            "time_frame": "Up to 30 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The criteria for nPR and PR based on IWCLL guideline are shown below.\nnPR: Fulfills all CR criteria other than residual lymphoid nodules confirmed by bone marrow examination.\nPR: Fulfills two or more items from Group A and one or more items from Group B for a minimal duration of 8 weeks.\nGroup A;\n50% or greater reduction in lymphocyte count in peripheral blood from baseline\n50% or greater reduction (size reduction) in Sum of the products of the greatest diameters (SPD) and no new lesion emergence or no new enlarged lymph node\nA decrease in the size of the liver and/or spleen by 50% more\nA decrease in marrow infiltration or lymphoid nodules by 50% more Group B;\n1) Neutrophil count \uff1e1.5\u00d710^9/L or 50% improvement from baseline 2) Platelet count \uff1e100\u00d710^9/L or 50% improvement from baseline 3) Hemoglobin 11.0 g/dL or 50% improvement from baseline without transfusions", 
                "measure": "National Cancer Institute-sponsored Working Group (NCI-WG) response rate (CR+nPR+PR) based on IWCLL guideline", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }, 
            {
                "measure": "Complete remission rate (CR+CRi) based on IWCLL guideline", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }, 
            {
                "description": "The period from the first day of the study drug administration (Day1) to progressive disease (PD), recurrence/relapse, or death.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }, 
            {
                "description": "The period from the day of CR or PR confirmation to recurrence/relapse.", 
                "measure": "Duration of remission", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }, 
            {
                "description": "The period from the date of patient registration to the date of death.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 months"
            }, 
            {
                "description": "All undesirable medical events experienced by the subject treated with the investigational product (including abnormal changes in laboratory values) are treated as adverse events and evaluated for safety.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 32 weeks"
            }, 
            {
                "description": "Analysis of hematology, clinical chemistry, urinalysis, immunology, and flow cytometry will be performed.", 
                "measure": "Number of subjects with clinically significant laboratory test values", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and up to 32 weeks"
            }, 
            {
                "description": "Analysis of vital signs, body weight, body surface area, and ECOG performance status will be performed.", 
                "measure": "Number of subjects with clinically significant physical examination values", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 32 weeks"
            }
        ], 
        "source": "SymBio Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SymBio Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}